Stay updated on Pembrolizumab + Chemo +/- Lenvatinib in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Chemo +/- Lenvatinib in Lung Cancer Clinical Trial page.

Latest updates to the Pembrolizumab + Chemo +/- Lenvatinib in Lung Cancer Clinical Trial page
- Check3 days agoChange DetectedLocation naming updated to Respublika and Kazan, Tatarstan; maximum duration extended to 58 months; revision bumped to v3.0.2 with an estimated last-update flag and new dates added.SummaryDifference0.4%
- Check10 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or important information.SummaryDifference0.1%
- Check18 days agoChange DetectedThe webpage has undergone significant updates, including the addition of numerous locations across various countries and the inclusion of drug information for specific medications, while also removing outdated location references and some drug information.SummaryDifference16%
- Check25 days agoChange DetectedThe page has updated the title of a study on Lenvatinib and Pembrolizumab for metastatic nonsquamous NSCLC, changing 'Non-Small-Cell Lung Cancer' to 'NSCLC'.SummaryDifference0.1%
- Check32 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
- Check39 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.0%
Stay in the know with updates to Pembrolizumab + Chemo +/- Lenvatinib in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Chemo +/- Lenvatinib in Lung Cancer Clinical Trial page.